Clinical trials: Metastatic Colorectal Neoplasms
Unresectable Metastatic Colorectal Cancer
OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
- Trial name
- VELVET (NCT01802684)
- Testing
- aflibercept
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Results from randomized clinical trials and intervention studies have suggested that implementation of a CRC screening program for…
- Trial name
- NCT00122187
- Testing
- Electronic Consult System
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- US Department of Veterans Affairs
Colon Cancer
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Trial name
- NCT03426904
- Testing
- Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX
- Where
- 4 sites in South Korea
- Volunteers
- 708 people
- Sponsor
- Kyungpook National University Hospital
Colorectal Cancer, Colorectal Adenocarcinoma
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
The purpose of this research study is: To find out how safe the study drug, pembrolizumab, is when combined with stereotactic body radiotherapy (SBRT) to the liver.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02837263
- Testing
- Stereotactic body radiotherapy (SBRT), Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
CRC
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
The study consists of the two parts, phase IIa and phase IIb.
- Trial name
- mCRC (NCT05233332)
- Testing
- HL-085, Vemurafenib
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Colorectal Neoplasms, Neoplasm Metastases
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms
- Trial name
- SERENADE (NCT02246634)
- Testing
- Diffusion Weighted MRI scan
- Where
- 13 sites in United Kingdom
- Volunteers
- 282 people
- Sponsor
- Imperial College London
Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary Objective: To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those…
- Trial name
- AFEQT (NCT01670721)
- Testing
- AFLIBERCEPT, Irinotecan, Fluorouracil
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Sanofi
Neoplasm Metastasis, Colorectal Neoplasms
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences.
- Trial name
- NCT00037180
- Testing
- Celecoxib, Irinotecan, 5-fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 212 people
- Sponsor
- Pfizer
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer (Locally Advanced or Metastatic), Lymphoma
Remote Monitoring and Symptom Management Digital Application
The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
- Trial name
- ASSIST (NCT07553572)
- Testing
- ASSIST phone application
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Patrick C. Johnson, MD
Metastatic Colorectal Cancer, MSS
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Fluorouracil and oxaliplatin-based combined with molecular targeted drugs are still the main treatment strategies for patients with advanced metastatic colorectal cancer (mCRC).
- Trial name
- NCT06415851
- Testing
- mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhangfa Song
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Neoplasm Metastasis
Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
Currently there is no one standard of care for older patients with metastatic colorectal cancer. The study will examine the tumor response to capecitabine, oxaliplatin, plus bevacizumab.
- Trial name
- NCT00120172
- Testing
- oxaliplatin, capecitabine, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Geriatric Oncology Consortium
Colorectal Cancer, Colon Cancer
Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
This study is for patients with colorectal cancer that has spread and has increased in size after standard treatments. This study is being done to find out how long it takes their tumors to grow after treatment with the…
- Trial name
- NCT00159445
- Testing
- gemcitabine, capecitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Southern California
Colorectal Cancer, Liver Metastases
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
- Trial name
- NCT05797077
- Testing
- Colorectal resection surgery., FOLFOX chemotherapy regimen, Capecitabine
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Metastatic Colorectal Cancer，NED
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED).
- Trial name
- CAMCO2 (NCT05360277)
- Testing
- Tislelizumab + Capecitabine, Best supportive care
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Yanhong Deng
Triple Negative Breast Cancer Metastatic, Melanoma Metastatic
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma.
- Conditions
- Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- NCT06889610
- Testing
- MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients.
- Trial name
- NCT05634590
- Testing
- Fruquintinib, FOLFIRI, mFOLFOX6
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol
A prospective, multicenter imaging Delphi survey among European radiological societies for mCRC imaging standardization.
- Trial name
- NCT04656782
- Testing
- Imaging survey, Facilitation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Ludwig-Maximilians - University of Munich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.